A Rare Haplotype of the RET Proto-Oncogene Is a Risk-Modifying Allele in Hirschsprung Disease  by Griseri, Paola et al.
Am. J. Hum. Genet. 71:969–974, 2002
969
Report
A Rare Haplotype of the RET Proto-Oncogene Is a Risk-Modifying Allele
in Hirschsprung Disease
Paola Griseri,1 Barbara Pesce,1 Giovanna Patrone,1 Jan Osinga,4 Francesca Puppo,1
Monica Sancandi,1 Robert Hofstra,4 Giovanni Romeo,3 Roberto Ravazzolo,1,2
Marcella Devoto,2,5 and Isabella Ceccherini1
1Laboratorio di Genetica Molecolare, Istituto G. Gaslini, and 2Dipartimento di Oncologia, Biologia e Genetica, Universita` di Genova,
Genova, Italy; 3Cattedra di Genetica Medica, Universita` di Bologna, Bologna, Italy; 4Department of Medical Genetics, University of
Groningen, The Netherlands; and 5Department of Research, Nemours Children’s Clinic, Wilmington, DE
Hirschsprung disease (HSCR) is a common genetic disorder characterized by intestinal obstruction secondary to
enteric aganglionosis. HSCR demonstrates a complex pattern of inheritance, with the RET proto-oncogene acting
as a major gene and with several additional susceptibility loci related to the Ret-signaling pathway or to other
developmental programs of neural crest cells. To test how the HSCR phenotype may be affected by the presence
of genetic variants, we investigated the role of a single-nucleotide polymorphism (SNP), 2508CrT (S836S), in exon
14 of theRET gene, characterized by low frequency among patients withHSCR and overrepresentation in individuals
affected by sporadic medullary thyroid carcinoma. Typing of several different markers across the RET gene dem-
onstrated that a whole conserved haplotype displayed anomalous distribution and nonrandom segregation in families
with HSCR. We provide genetic evidence about a protective role of this low-penetrant haplotype in the pathogenesis
of HSCR and demonstrate a possible functional effect linked to RET messenger RNA expression.
Hirschsprung disease (HSCR [MIM 142623]) (incidence
1/5,000 live births) is a developmental disorder char-
acterized by the absence of enteric neurons in distal
segments of the gastrointestinal tract, which causes
intestinal obstruction in neonates and severe consti-
pation in adults. Several lines of evidence suggest a
multigenic pattern of inheritance for the disease: a
distorted sex ratio (M:F p 4:1), incomplete pene-
trance, variable expressivity, and the existence of syn-
dromic forms (Badner et al. 1990; Gabriel et al. 2002).
Since 1994, many studies have indicated that the RET
proto-oncogene (MIM 164761), which encodes a ty-
rosine kinase receptor, is the major HSCR gene and
have ascribed the disease to loss-of-function muta-
tions of the gene. To date, RET mutations account
for !30% of sporadic cases, and a small number of
patients (5%–10%) show alterations in other genes
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(GDNF, NRTN, ECE1, EDN3, EDNRB, SOX10, and
SIP1 [reviewed by Parisi and Kapur 2001]).
In view of the central role played by the RET proto-
oncogene in HSCR development, we have investigated
the existence ofRET alleles that could act as susceptibility
factors and modulate the expression of the disease. In our
previous work, we analyzed a 2508CrT SNP in exon 14
of the RET gene (S836S), finding that the T variant was
less frequent in patients with HSCR (1 [0.5%] of 184
alleles) compared with the normal population (30 [8.5%]
of 352 alleles) ( by Fisher’s exact test) (GriseriPp .00023
et al. 2000b). We also demonstrated that the anomalous
allelic distribution was due to nonrandom segregation of
the T and C alleles in Italian families with HSCR (trans-
mission/disequilibrium test ). In the presentPp .008
study, we have attempted to determine whether the ob-
served segregation distortion is due to an increased risk
of developing HSCR conferred by the C allele or to
a protective effect of the T allele.
Using four SNPs distributed along the whole gene,
we reconstructed RET haplotypes in seven Italian
families informative for SNP14. The SNPs selected are
the closest and the most distant known on each side of
the 2508CrT locus, covering a total region of 25.3 kb
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Table 1
RET Haplotypes and Their Frequencies in Parents of Italian and







GGTCC 7 (100) 19 (95)
ATCCC … 1 (5)
Transmitted:
ATCCCb 2 (28.6) 8 (40)
AGCCTc 3 (42.8) 7 (35)
AGCGT … 1 (5)
AGCCC … 3 (15)
GTCCCd 2 (28.6) …
GGTCC … 1 (5)
a For Italian (7) and Dutch (20) patients with HSCR, haplotypes
were determined for all parents who were heterozygous for the SNP14
CrT polymorphic variant.
b Associated once with the R813W RET mutation.
c Associated once with the I647I RET mutation.
d Associated once with the C157Y RET mutation.
Figure 1 Physical map of RET markers. RET genomic region (not to scale) is represented, together with relative distances between SNP
markers. Hatched rectangle indicates the promoter region. Analysis of SNPs was reported by Ceccherini et al. (1994). Analysis of the SNP
IVS1947CrT was performed using primers int19F (5′-TGG AGT GAC CGG CCA TCT CT-3′) and int19R (5′-AAG CAT CAC AGA GAG
GAA GG-3′) and the MnlI restriction enzyme.
(fig. 1). Among these markers, the 135GrA in exon 2
(A45A), the 2307TrG in exon 13 (L769L), and the
2712 CrG in exon 15 (S905S) represent known synon-
ymous polymorphisms (Ceccherini et al. 1994), whereas
the IVS1947CrT is a new polymorphic intronic var-
iant and is described here for the first time (see legend
to fig. 1). Reconstruction of RET haplotypes in the seven
selected families with HSCR showed that the T allele of
SNP14 (which is never transmitted from the informative
C/T parents to the affected children) lies on a single
haplotype, defined by the wild-type G of SNP2, the var-
iant G of SNP13, and the two most-common C alleles
of SNP15 and SNP19 (GGTCC) (table 1). On the other
hand, the C allele of SNP14 (which is always transmitted
from heterozygous individuals to their affected off-
spring) was found to be associated with three different
combinations of polymorphisms (table 1).
To evaluate haplotype frequencies in the general
population of Italy, we typed 80 Italian healthy con-
trol individuals for the same five SNPs. We calculated
the frequency of the common alleles: G p 0.73 for
SNP2, T p 0.79 for SNP13, C p0.93 for SNP14, C
p 0.83 for SNP15, and C p 0.87 for SNP19. No
significant deviation from Hardy-Weinberg equilib-
rium was observed for any polymorphism. The dis-
tribution of haplotypes, which was estimated using
the EM algorithm as implemented in the EHPlus pro-
gram (Zhao et al. 2000), demonstrated that GGTCC
was the only haplotype that included the T variant of
SNP14 in the Italian population, with a frequency of
7.2% in healthy control individuals.
We further tested 156 Dutch patients with HSCR for
the distribution of the C/T variant of exon 14, and we
found a frequency of 1.0% (3 of 312 chromosomes) of
the T allele, a frequency lower than the 2.5% (2 of 80
alleles) calculated for the 40 population-based control
individuals matched on the basis of geographical region
(difference not significant). Further analysis of 289 par-
ents of Dutch patients with HSCR allowed us to identify
20 C/T heterozygotes (T allele frequency 3.5%), among
whom only one transmitted the T allele to the affected
child, with a significant deviation from random trans-
mission (transmission/disequilibrium test ).Pp .000057
Haplotype determination in the same 20 Dutch infor-
mative families established that the T allele of SNP14
was always present on the same conserved haplotype,
namely GGTCC, and the C variant was associated with
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Figure 2 Families with HSCR with co-occurrence of RET mutations and the GGTCC haplotype. RET-mutated alleles are shown in black,
and the GGTCC haplotype is shown in gray. Segregating RET mutations are indicated below each pedigree.
five different haplotypes (table 1). Our data suggest that
in the Italian and Dutch populations a single T haplotype
(GGTCC) is present and that it is characterized by non-
random transmission in families with HSCR.
To determine the extension of the conserved region
containing the T variant of SNP14, we characterized
the promoter region of the seven Italian parents with
the C/T variant, using two polymorphic nucleotide sub-
stitutions: a GrA transition and a CrA transversion
located at 5 and 1 bp from the transcription start
site, respectively (M.S., unpublished data). Analysis of
these two markers showed three different sequence com-
binations, namely, GA (2/7 alleles), GC (4/7 alleles), and
AA (1/7 alleles), that were associated with the GGTCC
haplotype. The presence of different genotypes of the
promoter region restricts the extension of the conserved
region and defines the 5′ boundary of the haplotype.
These data suggest that the mutation that generated the
T allele occurred once on a unique haplotype. Different
recombinations in the 23.5-kb region from start codon
to exon 2 of the RET gene have subsequently broken
the allelic association with the promoter region. Both
the large dimension of intron 1 and its high content
in sequences of short interspersed elements and long
interspersed elements could explain the high degree of
recombination between the promoter and exon 2, sug-
gesting the existence of hotspots of genomic rearrange-
ments in the RET locus.
The low frequency of the GGTCC haplotype in pa-
tients with HSCR suggests that it could have a role as
a low-penetrance “gain of function”RET allele and that,
for this reason, it may exert a protective effect against
development of megacolon. To test this hypothesis, we
analyzed the genotype-phenotype correlation in families
with HSCR that showed segregation of this haplotype.
First, we focused on the only three families who had co-
occurrence of both a RET mutation and the GGTCC
haplotype and were characterized by nontransmission of
this haplotype to the affected child (fig. 2). In family 1,
the father was found to be a compound heterozygote
for the R813W mutation in exon 14 and the T variant
of SNP14 (on the GGTCC haplotype), and he appeared
healthy; the daughter, who inherited only the mutated
allele, was affected by HSCR. In family 2, a synonymous
substitution (1941CrT [I647I], which was previously
demonstrated to interfere with RET splicing but was not
sufficient to determine the HSCR phenotype by itself)
was transmitted to the patient with HSCR from an
unaffected mother who carried the GGTCC haplotype
on the other allele (Auricchio et al. 1999). Finally, in
family 3, which was characterized by recurrence of a
whole RET gene deletion, the hemizygous mother, with
GGTCC as the only RET allele, unexpectedly did not
show any symptom of the disease; however, the daughter,
who was hemizygous for a different allele, was affected
with HSCR.
We have also analyzed the phenotype of all the avail-
able patients with HSCR who were carriers of the T
allele, irrespective of nationality and type of mutation
(familial or sporadic). The DGGE screening of 188 pa-
tients with HSCR showed only four C/T heterozygotes.
Two patients with sporadic disease were affected by
Down syndrome; the association between HSCR and
Down syndrome has been frequently observed and has
led other investigators to hypothesize the presence of a
HSCR susceptibility gene on chromosome 21 (Puffen-
berg et al. 1994). In the third individual, we detected a
de novo RET substitution (IVS1247CrT), which was
demonstrated to interfere with RET splicing; this mu-
tation was in a cis position with the SNP14 T allele and
may have counteracted its protective effect (Griseri et
al. 2000a). Finally, in an Italian family with several
instances of HSCR among the father’s relatives, the
two affected sibs shared the same paternal haplotype
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Figure 3 Results of semiquantitative RT-PCR. Cell growth conditions were reported elsewhere (Auricchio al. 1999). Sodium butyrate was
dissolved in water (1 M stock solution) and was delivered to cells at a final concentration of 5 mM. Treatment was performed overnight. The
fluorescence-based semiquantitative PCR approach has been described elsewhere (Patrone et al. 2000). Regression lines correlating PCR yield
to cDNA concentration were determined for each sample by pooling three dilutions of three independent PCRs. Relative transcript abundance
was evaluated as the ratio between the RET and the G3PDH line slopes. A and E, Haplotypes of three unrelated control individuals and two
unaffected members of a family, sharing an identical-by-descent allele (shaded boxes). From top to bottom, the two alleles of promoter region
(in italics) SNP2, SNP13, SNP14 (bold), SNP15, and SNP19 are indicated. B and F, Semiquantitative analysis of total RET mRNA (relative
values). C and G, the expression profiles of Ret isoform 51 (black) and isoform 9 (gray) are reported (absolute values). D and H, Graphical
representation of RET51:RET9 ratio.
(GTCCC) with no RET mutations in the coding re-
gion. Interestingly, one sib had inherited the maternal
GGTCC allele and was affected with a short form of
HSCR. Her sister, who inherited the alternative maternal
haplotype (GTCCC), showed a severe phenotype of total
colonic aganglionosis.
Two hypotheses can be formulated about the protec-
tive role of the GGTCC haplotype: (1) the effect is re-
lated to the particular combinations of polymorphic var-
iants (combinatory hypothesis); (2) the effect is due to
a genetic variant, as yet unidentified, in linkage dis-
equilibrium with this haplotype (linkage disequilibrium
hypothesis).
The hypothesis of an additive/combinatorial effect of
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multiple polymorphisms is intriguing, considering that
single polymorphic variants were found to be differen-
tially associated with HSCR (Borrego et al. 2000; Fitze
et al. 2002). In agreement with this hypothesis, we noticed
that the GGTCC haplotype does not contain the A allele
of SNP2, which was suggested to be predisposing for
HSCR disease; in contrast, the A allele of SNP2 is over-
represented among the Italian and Dutch transmitted hap-
lotypes. As an alternative hypothesis, it is possible that
the effect of the GGTCC haplotype does not derive from
any of the single variants or their combinations. In this
case, our observations may be explained by the existence
of an additional variant, as yet unidentified, in linkage
disequilibrium with the GGTCC haplotype.
In the attempt to explain the protective effect of the
GGTCC haplotype, we performed a semiquantitative
RT-PCR, using RNA from lymphoblastoid cells treated
with sodium butyrate. The histone deacetylase inhibitor
sodium butyrate up-regulates both the levels of RET
mRNA and the nuclear transcription rate in RET-neg-
ative cells, such as lymphoblasts (Puppo et al. 2002).
We evaluated RET mRNA levels in lymphoblastoid cells
obtained from three normal control individuals with dif-
ferent genotypes of SNP14; one homozygote C/C, one
heterozygote C/T, and one homozygote T/T (fig. 3). We
found the highest level of RET expression in the C/C
homozygote, the second highest level in the C/T hetero-
zygote, and the lowest level in the T/T homozygote (50%
of the C/C control) (fig. 3B). To verify that the observed
effect could be exclusively ascribed to the GGTCC hap-
lotype and not to other differences in the genetic back-
ground of the three individuals, we performed the same
experiments in two additional healthy control individ-
uals, a father and his son, who shared an identical-by-
descent C allele (see family 3 in fig. 2). In this case, the
difference in the level of RET transcript could be at-
tributed to a single different haplotype harboring the C
(father) or the T (son) variant of SNP14 (fig. 3E). This
test confirmed that a decreased expression of the RET
gene was related to the presence of the GGTCC hap-
lotype (fig. 3F).
To investigate further the expression profile of the
GGTCC haplotype (and considering that the conserved
region is maintained at least down to intron 19), we
analyzed the presence of 3′ alternatively spliced RET
isoforms. There are two major isoforms, Ret9 and
Ret51, which differ in the amino acid sequence of the
C-terminal tail, as a result of alternative splicing and
different use of terminal codons (Myers et al. 1995). To
date, compelling pieces of evidence indicate that RET9
and RET51 present distinct biochemical and biological
properties, playing different roles in tumorigenesis and
development (Ivanchuck et al. 1998; Le Hir et al. 2000).
Analysis of the same five control individuals mentioned
above showed that, in the presence of the GGTCC hap-
lotype, a clear inversion in the proportion of the two
transcripts occurred—resulting from a relative increase
of RET51 expression with respect to RET9 (fig. 3C and
3G)—as is also revealed by isoform histograms and
graphical representation of RET51:RET9 ratio (fig. 3D
and 3H).
Although these experiments, performed on sodium
butyrate–treated lymphoblasts, do not reflect tissue-
specific RET expression, our results indicate a decrease
in RET mRNA and an unbalance in RET isoforms as-
sociated with the GGTCC haplotype.
The lower RET transcription rate that we have ob-
served in association with the GGTCC haplotype seems
to be a contrast with the putative protective effect of the
latter allele, since the pathogenesis of HSCR is generally
ascribed to loss of function or haploinsufficiency of the
RET gene. This reduced expression could be explained
by a selective underproduction of one of the two iso-
forms, RET9, and the resulting enrichment of the other,
RET51. The identification of a missense RET mutation
within exon 20 (iso51-specific M1064T) in a family with
HSCR suggests that RET51 (long isoform) is essential
to normal enteric development (Attie` et al. 1995), and
the relative increase of RET51 that we observed may
represent a protective factor. Nevertheless, experiments
with recently developed transgenic mice support the idea
that RET9 plays a central role with respect to RET51
in vertebrate development (de Graaf et al. 2001). On
the basis of these apparently discordant studies, we sug-
gest that there may be a critical role, not only for the
absolute amount of the two isoforms but also for the
RET51:RET9 ratio; this would agree with a possible
cross-talk between the two proteins: in this respect, for-
mation of homo- and heterodimers between long and
short isoforms has already been demonstrated (Alberti
et al. 1998).
In conclusion, we have demonstrated the existence of
a rare RET haplotype that acts as a risk-modifier allele
in HSCR and related neurocristopathies, and we have
associated this effect with the haplotype’s peculiar ex-
pression profile (a decrease in the total amount of RET,
with enrichment of the RET51 isoform). We are now
investigating the characterization of the genetic/func-
tional variant responsible for this effect.
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